Last reviewed · How we verify
Peri
Peri, marketed by Ospedale San Raffaele, holds a position in the pharmaceutical market with its key composition patent expiring in 2028. The drug's primary strength lies in its current market presence, leveraging its established patient base and clinical validation. The primary risk is the potential increase in competition post-patent expiry in 2028, which could impact revenue and market share.
At a glance
| Generic name | Peri |
|---|---|
| Also known as | Perindopril |
| Sponsor | Ospedale San Raffaele |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Investigation of Blood-Brain-Barrier Breakdown Using Manganese Magnetic Resonance Imaging in Drug-Resistant Epilepsy (PHASE1)
- SURGIMEDIA: A Patient Randomized Control Trial of Utilization of Multimedia for Enhanced Surgical Consent (NA)
- Disorders of the Acute Phase Response Following Trauma and Invasive Surgery (NA)
- Building Access to Food Through Systems and Solidarity (NA)
- Impact of COVID-19 Pandemic on Single-stage Laparoscopic Cholecystectomy and Laparoscopic Common Bile Duct Exploration Service
- Microplastics in Pancreas: Oncologic and Metabolic Impact
- Thumb Base Osteoarthritis: Ultrasound-guided Platelet-rich Plasma Versus Placebo Injection (PHASE2)
- Consequences of Antiangiogenic Factors Involved in Preeclampsia on Intra-uterine Growth Restricted Preterm Newborn
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |